Although further in vivo investigations using the HGPS mouse model are needed, we propose that baricitinib treatment could ameliorate or delay the development of generalized lipodystrophy, which is known to affect the metabolism and the appearance of children with HGPS. The gene discussed is ZMPSTE24; the disease is Hutchinson-Gilford progeria syndrome.